Burkitt lymphoma is one of the fastest-growing cancers known to medicine, with tumors capable of doubling in size every 24 hours. It’s a type of B-cell non-Hodgkin lymphoma that accounts for less than 1% of adult non-Hodgkin lymphomas in the United States but makes up over 40% of childhood non-Hodgkin lymphoma cases. Despite its aggressive nature, intensive chemotherapy can produce high response rates, making early recognition and rapid treatment critical.
Three Distinct Types
Burkitt lymphoma comes in three forms, each tied to different populations and geography.
Endemic Burkitt lymphoma is a childhood cancer concentrated in malaria-heavy regions of sub-Saharan Africa and Papua New Guinea. It peaks between ages 6 and 8, affects boys more often than girls, and is linked to Epstein-Barr virus (EBV) in roughly 95% of cases. The jaw and facial bones are classic sites of involvement in this form.
Sporadic Burkitt lymphoma is the type seen worldwide, including in the U.S. and Europe. The median age at diagnosis is 10, with additional peaks around age 40 and 75. Males are again more commonly affected. EBV plays a smaller role here, showing up in only 10 to 30% of cases, mostly in patients over 50.
Immunodeficiency-associated Burkitt lymphoma primarily affects people living with HIV and was the first lymphoma described in connection with AIDS. It’s considered an AIDS-defining condition. The median age is 40 to 45, and unlike the other two types, it affects men and women at similar rates. EBV is found in 20 to 40% of these cases.
What Drives the Cancer
Nearly all Burkitt lymphoma cases share a defining genetic event: a piece of chromosome 8 breaks off and attaches to chromosome 14. This swap places a growth-promoting gene called MYC next to a region that’s normally very active in immune cells. The result is that MYC gets permanently switched on, forcing B cells (a type of white blood cell) to multiply uncontrollably. This constant “go” signal is what gives Burkitt lymphoma its extraordinary growth speed. Rarer translocations involving chromosomes 2 or 22 can produce the same effect through a similar mechanism.
Common Symptoms and Presentation
Because of its rapid doubling time, Burkitt lymphoma can produce noticeable symptoms within days to weeks. The presentation depends on the type.
In sporadic cases, the abdomen is the most common site. People typically experience abdominal pain, swelling, and fluid buildup. Lymph nodes in the abdomen and the tissue around the intestines enlarge quickly. The cancer frequently involves the lower part of the small intestine, the cecum (where the small and large intestines meet), the stomach, and surrounding tissue. It can also spread to the kidneys, liver, spleen, ovaries, testes, and central nervous system.
In endemic cases, the jaw or other facial bones are often the first site affected, producing visible swelling that grows rapidly. Abdominal involvement is also common in these patients.
General symptoms like fever, drenching night sweats, and unintentional weight loss can occur with any form. Because the tumor grows so fast, the window between first symptoms and diagnosis is often remarkably short.
How It’s Diagnosed
A biopsy is essential. Under the microscope, Burkitt lymphoma has a distinctive look that pathologists call a “starry sky” pattern. The tumor is made up of densely packed, medium-sized cells that form a dark blue background (the “sky”). Scattered among them are immune cells called macrophages that have engulfed debris from the rapidly dying and dividing tumor cells. When tissue is prepared on a slide, these macrophages appear as pale round spots (the “stars”) against the dark tumor background.
Pathologists confirm the diagnosis using specific protein markers on the surface of the tumor cells. The cells are positive for markers associated with B cells and a protein involved in cell division that reflects the tumor’s extremely high growth rate, often approaching 100% of cells actively dividing at any given time. Genetic testing confirms the characteristic MYC translocation.
Staging
Burkitt lymphoma is staged from I through IV. Stages I and II are considered limited disease, meaning the cancer is in one site or in multiple sites on the same side of the diaphragm. Stage III indicates more widespread disease in the abdomen or chest without involvement of the bone marrow or brain. Stage IV means the cancer has reached the bone marrow, the central nervous system, or both. Patients whose abdominal tumors are completely removed surgically may be classified at a lower stage, which carries a better outlook.
Treatment Approach
Short, intensive, multi-drug chemotherapy is the standard treatment. The regimens are aggressive by design because the cancer itself is aggressive, and slower approaches give the tumor time to outpace treatment. The most commonly used protocols alternate between different combinations of chemotherapy drugs delivered in rapid cycles.
Adding rituximab, a targeted therapy that attaches to a protein on B cells, has improved outcomes. In a large clinical trial, combining rituximab with chemotherapy improved both event-free and overall survival without increasing side effects. Overall response rates with rituximab-containing regimens reach approximately 88%, compared to 75% without it.
A critical part of every treatment plan is preventing the cancer from reaching or recurring in the brain and spinal cord. Because Burkitt lymphoma has a tendency to spread to the central nervous system, all standard regimens include CNS-directed strategies. These involve chemotherapy drugs delivered directly into the spinal fluid through lumbar punctures, along with high-dose intravenous drugs capable of crossing the blood-brain barrier. Before treatment begins, doctors check for existing CNS involvement using imaging and analysis of spinal fluid.
The choice of regimen matters for CNS protection. Data from a large multicenter study found that certain intensive regimens had a 3-year CNS recurrence risk of only 3 to 4%, while a less intensive alternative carried a 13% recurrence risk. The difference appeared to stem partly from the stronger CNS-penetrating drugs in the intensive protocols and partly from how strictly clinicians followed the required spinal fluid testing and intrathecal injection schedules.
Tumor Lysis Syndrome
One of the most dangerous complications of treating Burkitt lymphoma isn’t the cancer itself but what happens when the cancer dies too quickly. Tumor lysis syndrome occurs when massive numbers of cancer cells break apart at once, flooding the bloodstream with their contents. This can overwhelm the kidneys and throw off the body’s chemical balance, leading to dangerously high levels of potassium, phosphorus, and uric acid, along with a sharp drop in calcium.
Advanced Burkitt lymphoma is classified as high risk for this complication. In severe cases, tumor lysis syndrome can cause kidney failure, seizures, or life-threatening heart rhythm problems. The good news is that medical teams anticipate this and take preventive steps before chemotherapy even begins. Prevention centers on aggressive IV fluids to keep the kidneys flushing out waste, medications to lower uric acid levels, and frequent blood monitoring during the first several days of treatment. Patients are also advised to avoid anti-inflammatory pain medications and certain contrast dyes that can stress the kidneys during this vulnerable period.
Outlook and Survival
Burkitt lymphoma is one of the most curable aggressive cancers when treated with appropriate intensive chemotherapy. Children generally fare better than adults. Pediatric cure rates with modern protocols exceed 90% for limited-stage disease and remain high even for advanced cases. Adults have somewhat lower cure rates, particularly those over 40 or those with involvement of the bone marrow or central nervous system at diagnosis.
Factors that influence prognosis include the stage at diagnosis, whether the CNS is involved, the patient’s age and overall health, and how completely the cancer responds to the first round of treatment. People with HIV-associated Burkitt lymphoma have seen significant improvements in outcomes as antiretroviral therapy has allowed them to tolerate full-dose chemotherapy regimens. Because the cancer grows so rapidly, delays in starting treatment can meaningfully affect results, making prompt diagnosis and referral to a specialized cancer center important.